聞泰科技:擬收購安世集團上層持股結構中的相關少數股東權益
格隆匯3月11日丨聞泰科技(600745.SH)公佈,公司擬通過發行股份等方式收購包括合肥芯屏產業投資基金(有限合夥)(“合肥芯屏”)持有的北京廣匯資產管理中心(有限合夥)(“北京廣匯”)99.9521%的財產份額在內的Nexperia Holding B.V. (“安世集團”)上層持股結構中的相關少數股東權益。
鑑於目前交易各方對此次交易僅達成初步意向,與合肥芯屏簽署了意向性框架協議,但有關事項尚存在不確定性,為保證公平信息披露,維護投資者利益,避免造成公司股價異常波動,根據有關規定,經公司向上海證券交易所申請,公司股票自2020年3月12日開市起停牌,公司承諾停牌時間不超過10個交易日。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.